Cellyan Biotechnology (HKPD) Long-Term Deferred Tax (2024)
Cellyan Biotechnology's (HKPD) quarterly Long-Term Deferred Tax came in at $2.2 million in Q3 2024, up 71.54% on a QoQ basis from $1.3 million in Q1 2024.
Cellyan Biotechnology (HKPD) Long-Term Deferred Tax (2024) Analysis & Trends
Cellyan Biotechnology (HKPD) has 1 years of Long-Term Deferred Tax data on file, last reported at $2.2 million in Q3 2024.
- On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $2.2 million in Q3 2024; TTM through Sep 2024 was $2.2 million, a N/A change from a year earlier, with the FY2024 full-year figure at $1.3 million, changed N/A from the prior year.
- Long-Term Deferred Tax for Q3 2024 stood at $2.2 million, up from $1.3 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for HKPD reached as high as $2.2 million in Q3 2024 and fell as low as $1.3 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Mckesson | 105.15 Bn | 101.18 Bn | 4.04 Bn |
| 2 | Cencora | 60.58 Bn | 58.40 Bn | 3.59 Bn |
| 3 | Cardinal Health | 53.81 Bn | 49.87 Bn | 2.50 Bn |
| 4 | Henry Schein | 9.71 Bn | 9.57 Bn | 1.07 Bn |
| 5 | Akso Health | 3.28 Bn | 3.28 Bn | - |
| 6 | 111 | 651.73 Mn | 572.63 Mn | 23.58 Mn |
| 7 | Accendra Health | 248.02 Mn | -88.86 Mn | 278.03 Mn |
| 8 | Edap Tms | 230.14 Mn | 215.14 Mn | 8.15 Mn |
| 9 | VitaNova Life Sciences | 11.51 Mn | 11.01 Mn | 316,343.00 |
| 10 | Cellyan Biotechnology | 4.19 Mn | 3.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 1.26 Mn |